Drugmakers try to dodge Trump-era rare disease price cuts

Rare disease drugmakers are trying to protect their products from potential Trump administration price cuts, despite the President's previous efforts to lower drug costs. Meanwhile, GOP voters are pushing for tougher action on healthcare fraud. There is ongoing concern about Pharmacy Benefit Managers (PBMs) finding ways around new state laws.